Quoin Pharmaceuticals Expands Clinical Trial to Include International Patients

Shares in Quoin Pharmaceuticals (Nasdaq: QNRX) climbed in morning trading on Thursday after the company announced that it will expand its two ongoing clinical trials to include international patients. The specialty pharmaceutical company said that its first international trial site will be opened at a research hospital in Saudi Arabia. Quoin is conducting two studies under an open Investigational New Drug Application (IND), evaluating QRX003 as a treatment for the rare genetic disease, Netherton Syndrome (NS).

Quoin has engaged an experienced local Clinical Research Organization to manage the study locally.

The company said in a statement that the new clinical site is currently treating a number of NS patients who will now become eligible for recruitment into Quoin’s studies. Plans to open additional international clinical sites are at an advanced stage.

Commenting on the news, Quoin CEO, Dr. Michael Myers, said, “We are very pleased to announce this exciting development for our ongoing clinical studies. We hope that the opening of this first international site, which is currently treating Netherton patients, will speed up overall recruitment into our studies whilst expanding the diversity of the patient population being tested.

“We are working hard to open additional international sites to augment the five sites that are currently open in the US. Quoin is committed to completing recruitment into our clinical studies as expeditiously as possible with a view to potentially delivering the first approved treatment to this underserved patient population.”

In March 2024, Quoin received FDA clearance to recruit teen subjects aged 14 years and older into its two ongoing clinical trials for QRX003.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises five products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.





This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Quoin Pharmaceuticals Expands Clinical Trial to Include International Patients

Catie Corcoran

Biotech Editor